Justin P Zachariah1, Catherine J McNeal2, Laurel A Copeland3, Ying Fang-Hollingsworth3, Eileen M Stock3, FangFang Sun3, Joon Jin Song4, Sean T Gregory5, Jeffrey O Tom6, Eric A Wright7, Jeffrey J VanWormer8, Andrea E Cassidy-Bushrow9. 1. Lillie Frank Abercrombie Section of Pediatric Cardiology, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. Electronic address: Justin.zachariah@bcm.edu. 2. Department of Pediatrics, Baylor Scott & White Health, Temple, TX, USA; Department of Internal Medicine, Baylor Scott & White Health, Temple, TX, USA. 3. Center for Applied Health Research, Baylor Scott & White Health, Temple, TX, USA; Center for Applied Health Research, Department of Internal Medicine, Central Texas Veterans Health Care System, Temple, TX, USA. 4. Department of Statistical Sciences, Baylor University, Waco, TX, USA. 5. Department of Health Policy and Management, College of Public Health, University of South Florida, Tampa, FL, USA. 6. Kaiser Permanente Center for Health Research Hawaii, Honolulu, HI, USA. 7. Geisinger Center for Health Research, Danville, PA, USA; Department of Pharmacy Practice, Wilkes University, Wilkes-Barre, PA, USA. 8. Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Foundation, Marshfield, WI, USA. 9. Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA.
Abstract
BACKGROUND: Pediatric lipid management recommendations have evolved from selective screening to universal screening to identify and target therapy for genetic dyslipidemias. Data on the success of the selective screening guidelines for lipid testing, dyslipidemia detection, and lipid management are conflicting. OBJECTIVE: To determine temporal trends in lipid testing, dyslipidemia categories and pharmacotherapy in a cohort of 653,642 individual youth aged 2 to 20 years from 2002 to 2012. METHODS: Summary data on lipid test results, lipid-lowering medicine (LLM) dispensings, and International Classification of Diseases, Ninth Revision diagnoses were compiled from the virtual data warehouses of 5 sites in the Cardiovascular Research Network. Temporal trends were determined using linear regression. RESULTS: Among the average 255,160 ± 25,506 children enrolled each year, lipid testing declined from 16% in 2002 to 11% in 2012 (P < .001 for trend). Among the entire population, the proportion newly detected each year with low-density lipoprotein cholesterol >190 mg/dL, a value commonly used to define familial hypercholesterolemia, increased over time from 0.03% to 0.06% (P = .03 for trend). There was no significant change over time in the proportion of the yearly population initiated on LLM or statins specifically (0.045 ± 0.009%, P = .59 [LLM] and 0.028 ± 0.006%, P = .25 [statin]). CONCLUSIONS: Although lipid testing declined during 2002 to 2012, the detection of familial hypercholesterolemia-level low-density lipoprotein cholesterol increased. Despite this increased detection, pharmacotherapy did not increase over time. These findings highlight the need to enhance lipid screening and management strategies in high-risk youth.
BACKGROUND: Pediatric lipid management recommendations have evolved from selective screening to universal screening to identify and target therapy for genetic dyslipidemias. Data on the success of the selective screening guidelines for lipid testing, dyslipidemia detection, and lipid management are conflicting. OBJECTIVE: To determine temporal trends in lipid testing, dyslipidemia categories and pharmacotherapy in a cohort of 653,642 individual youth aged 2 to 20 years from 2002 to 2012. METHODS: Summary data on lipid test results, lipid-lowering medicine (LLM) dispensings, and International Classification of Diseases, Ninth Revision diagnoses were compiled from the virtual data warehouses of 5 sites in the Cardiovascular Research Network. Temporal trends were determined using linear regression. RESULTS: Among the average 255,160 ± 25,506 children enrolled each year, lipid testing declined from 16% in 2002 to 11% in 2012 (P < .001 for trend). Among the entire population, the proportion newly detected each year with low-density lipoprotein cholesterol >190 mg/dL, a value commonly used to define familial hypercholesterolemia, increased over time from 0.03% to 0.06% (P = .03 for trend). There was no significant change over time in the proportion of the yearly population initiated on LLM or statins specifically (0.045 ± 0.009%, P = .59 [LLM] and 0.028 ± 0.006%, P = .25 [statin]). CONCLUSIONS: Although lipid testing declined during 2002 to 2012, the detection of familial hypercholesterolemia-level low-density lipoprotein cholesterol increased. Despite this increased detection, pharmacotherapy did not increase over time. These findings highlight the need to enhance lipid screening and management strategies in high-risk youth.
Authors: Alpo Vuorio; Jaana Kuoppala; Petri T Kovanen; Steve E Humphries; Timo Strandberg; Serena Tonstad; Helena Gylling Journal: Cochrane Database Syst Rev Date: 2010-07-07
Authors: Karen L Margolis; Louise C Greenspan; Nicole K Trower; Matthew F Daley; Stephen R Daniels; Joan C Lo; Elyse O Kharbanda; Alan R Sinaiko; David J Magid; Emily D Parker; Malini Chandra; Heather M Tavel; Patrick J O'Connor Journal: Circ Cardiovasc Qual Outcomes Date: 2014-08-26
Authors: Albert Wiegman; Samuel S Gidding; Gerald F Watts; M John Chapman; Henry N Ginsberg; Marina Cuchel; Leiv Ose; Maurizio Averna; Catherine Boileau; Jan Borén; Eric Bruckert; Alberico L Catapano; Joep C Defesche; Olivier S Descamps; Robert A Hegele; G Kees Hovingh; Steve E Humphries; Petri T Kovanen; Jan Albert Kuivenhoven; Luis Masana; Børge G Nordestgaard; Päivi Pajukanta; Klaus G Parhofer; Frederick J Raal; Kausik K Ray; Raul D Santos; Anton F H Stalenhoef; Elisabeth Steinhagen-Thiessen; Erik S Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen; Olov Wiklund Journal: Eur Heart J Date: 2015-05-25 Impact factor: 29.983
Authors: Jorie Versmissen; Daniëlla M Oosterveer; Mojgan Yazdanpanah; Joep C Defesche; Dick C G Basart; Anho H Liem; Jan Heeringa; Jacqueline C Witteman; Peter J Lansberg; John J P Kastelein; Eric J G Sijbrands Journal: BMJ Date: 2008-11-11
Authors: A E Levenson; C E Milliren; S B Biddinger; C B Ebbeling; H A Feldman; D S Ludwig; S D de Ferranti Journal: Nutr Metab Cardiovasc Dis Date: 2017-01-03 Impact factor: 4.222
Authors: Emily F Gregory; Jeffrey M Miller; Richard C Wasserman; Roopa Seshadri; Robert W Grundmeier; David M Rubin; Alexander G Fiks Journal: Circ Cardiovasc Qual Outcomes Date: 2020-07-17
Authors: Swetha Sriram; Jennifer L St Sauver; Debra J Jacobson; Chun Fan; Brian A Lynch; Valeria Cristiani; Iftikhar J Kullo; Aida N Lteif; Seema Kumar Journal: Prev Med Rep Date: 2017-11-08
Authors: Justin H Berger; Jennifer A Faerber; Feiyan Chen; Kimberly Y Lin; Julie A Brothers; Michael L O'Byrne Journal: J Am Heart Assoc Date: 2022-03-18 Impact factor: 6.106
Authors: Justin H Berger; Feiyan Chen; Jennifer A Faerber; Michael L O'Byrne; Julie A Brothers Journal: Am Heart J Date: 2020-10-24 Impact factor: 4.749